Vistagen Therapeutics, Inc.

Greetings, and welcome to the Vistagen Therapeutics Fiscal Year and 2024 Corporate Update Conference Call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mark McPartland, Senior Vice President of Investor Relations.

Thank you, Joe. Good afternoon, everyone, and welcome to Vistagen's fiscal year-end 2024 corporate update conference call and webcast. This afternoon, we filed our annual report with the Securities Exchange Commission, or SEC, on SEC Form 10-K for our fiscal year-ended March 31st, 2024, and issued a press release providing an overview of our progress during our fiscal year 2024. We encourage you to review The press release and our 10-K, both of which can be found in the investor section of our website. During today's call, we'll make forward-looking statements regarding our business based on our current expectations and information. These forward-looking statements speak only as of today and except as required by law, we do not assume any duty to update in the future any forward-looking statements made today. Of course, forward-looking statements involve risks and uncertainties, And our actual results could differ materially from those anticipated by any forward-looking statements we make today. Additional information concerning risks and factors that could affect our business and the financial results is included in our fiscal year-end 2024 Form 10-K filed earlier today with the SEC and in the filings that we'll make with the SEC from time to time in the future, all of which are available in the investor section of our website and or on the SEC's website. With the formalities out of the way, we offer a warm welcome to all of our stockholders, sell-side analysts, and other interested in this agenda. I'm joined on our call today by Shawn Singh, our Chief Executive Officer, Cindy Anderson, our Chief Financial Officer, and Josh Prince, our Chief Operating Officer. Shawn will provide an update on our lead programs in our diversified neuroscience pipeline. After the conclusion of the prepared remarks, There will be a brief opportunity for questions from the sell-side analysts. As a reminder, the call is being webcast and will be available for replay after completion. The replay link can also be found in the investor section of our website. With that, I'd like to turn the call over to our Chief Executive Officer, Sean Singh.

Thank you, Mark. Sorry about that, everyone.